What Irvine Clinical Research does

Irvine Clinical Research is an independent, physician investigator-owned clinical trial site that conducts Phase II–IV sponsored studies in central nervous system (CNS), rheumatology, and obesity indications. The company's flagship site, founded in 2005 by Dr Elly Lee in Irvine, California, is co-located in the Alzheimer's Orange County building and operates an affiliated network of six research centers across Southern California (Long Beach, Riverside, Inglewood, West Los Angeles) and the Bay Area (Oakland). The bulk of its work centers on Alzheimer's disease and memory-loss trials, with secondary lines in depression and, more recently, obesity. The site participated in the landmark Eisai/Biogen lecanemab Phase III trial, which produced a 27% slowing of cognitive decline across 1,795 patients over 18 months.

The company's core operations are clinical-research-services oriented rather than product- or software-oriented. On-site capabilities include a CLIA-waived laboratory, certified phlebotomy, temperature-controlled drug storage with 24/7 monitoring, EKG/ECG, bladder ultrasound, uroflow, in-house EDC capability, and access to advanced neuroimaging including amyloid PET and tau PET using all major Alzheimer tracers (florbetapir/Amyvid, florbetaben/NeuraCeq, flutemetamol/Vizamyl, flortaucipir/Tauvid, MK-6240). Dr Elly Lee has served as PI on more than 300 trials over 20+ years and Dr Edward Zamrini has been PI/Co-PI on 73 AD/dementia trials since 1988, forming an experienced investigator bench.

Irvine Clinical Research generates revenue exclusively from contracts with pharmaceutical and biotech sponsors conducting sponsored Phase II–IV trials. There is no direct patient billing: all study-related care and medications are provided at no cost to qualified participants, with optional compensation for time and travel. Sponsors are engaged through direct field-sales relationships and the company offers rapid operational turnaround (two business days for regulatory documents and budgets/contracts) and accepts sponsors' Central IRBs to eliminate local IRB friction. Patient recruitment combines database and chart review, community outreach through the Alzheimer's Orange County partnership (25,000 annual touches), and direct inbound contact via phone and web form.

Name

Irvine Clinical Research

Legal name

Irvine Clinical Research

Website

https://irvineclinical.com

Company type

Private

Founded year

1978

Operating status

Operating

Headcount range

11–50 employees

Short description

Irvine Clinical Research is an independent, physician-owned clinical trial site conducting Phase II–IV sponsored studies in Alzheimer's disease, memory loss, depression, rheumatology, and obesity across a six-location network in Southern California and the Bay Area, serving pharmaceutical and biotech sponsors and providing no-cost investigational care to participants.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts) (HLAGACAC), Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG)

Keywords

• Clinical research services
• Alzheimer's clinical trials
• Memory loss studies
• Phase II-IV trials
• Independent research site

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Clinical Trial Sponsorship Contracts: Irvine Clinical Research operates as an independent, physician investigator-owned clinical trial site. Revenue is generated from contracts with pharmaceutical sponsors (pharma and biotech companies) conducting Phase II-IV clinical trials. Sponsors pay for study conduct, patient enrollment, data collection, and regulatory compliance. The company offers sponsors rapid regulatory document turnaround (two business days), budget/contract turnaround with signatory authority, and immediate PI availability for project management and CRA contacts.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Irvine Clinical Research operates as an independent, physician investigator-owned clinical trial site conducting Phase II-IV sponsored trials, primarily in CNS (Neurology and Psychiatry), rheumatology, and obesity therapeutic areas. The site delivers study conduct, patient enrollment, data collection, and regulatory compliance services to pharmaceutical and biotech sponsors, while providing no-cost medical care, investigational treatments, and study medications to qualified participants at its outpatient research centers.

Product overview

Irvine Clinical Research operates as an independent, multi-specialty, physician investigator-owned clinical research clinic conducting Phase II-IV sponsored clinical trials. The company's core offerings center on CNS (Neurology and Psychiatry) therapeutic areas, with primary focus on Memory Loss/Alzheimer's Disease studies, Depression clinical trials, and Obesity research studies. Services are delivered through their outpatient research center with affiliated neuroimaging services. All study-related care and medications are provided at no cost to qualified participants.

Differentiator

Problem solved

Functional benefit

Products and services

• Memory Loss Clinical Trials Phase II-IV sponsored clinical trials for memory loss, Alzheimer's disease, mild cognitive impairment, and related dementias. Provides no-cost medical exams, study medications, and brain imaging to qualified participants, with some compensation for time and travel.
• Depression Clinical Trials Clinical studies investigating new depression treatments for individuals suffering from symptoms of depression, chronic depression, or those whose current treatments are not effective. Provides free medical exams and potential compensation for time and travel.
• Obesity Clinical Trials Clinical studies for obesity treatment and weight management research, listed as upcoming/new studies, designed for adults interested in clinical trials for obesity and weight management treatments.
• Sponsored Clinical Trial Site Services Direct clinical trial site services for pharmaceutical and biotech sponsors conducting Phase II-IV trials in CNS (Neurology and Psychiatry), rheumatology, and obesity therapeutic areas. Includes rapid regulatory document turnaround (two business days), budget/contract turnaround with signatory authority, immediate PI availability, in-house CLIA-waived laboratory, and dedicated regulatory and contracts specialists as single points of contact.

Quantifiable outcome

• 27% slowing of cognitive decline in lecanemab Phase III trial involving 1,795 patients over 18 months
• +4 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered core and minor.

• EisaicoreOthersEisai was the sponsor of the landmark lecanemab Phase III clinical trial for Alzheimer's disease. Irvine Clinical Research was one of the trial sites. Lecanemab demonstrated a 27% slowing of cognitive decline in 1,795 patients over 18 months. This represents the company's most notable sponsored trial involvement to date.
• BiogencoreOthersBiogen co-sponsored the lecanemab (Leqembi) Phase III clinical trial alongside Eisai. Irvine Clinical Research was one of the trial sites. The drug targets amyloid plaque cleanup in the brain to treat and slow cognitive decline in early Alzheimer's disease patients.
• Alzheimer's Orange CountycoreStrategic or Co-development PartnerIrvine Clinical Research's flagship site is physically located in the Alzheimer's Orange County building, a community organization that reaches 25,000 people annually with educational outreach and support programs. This co-location provides a steady referral pipeline of engaged patients and families affected by memory loss.
• Healthy Brain Clinic (Dr Trinh, Long Beach)coreStrategic or Co-development PartnerPart of the Irvine Clinical Research network of affiliated memory research centers. Dr Trinh provides community-focused brain health research and gives 100+ educational talks annually, serving as director at Alzheimer's LA and Alzheimer's OC — two of the largest SoCal nonprofits serving AD patients.
• Riverside Clinical (Dr Cydney Osano)coreStrategic or Co-development PartnerNetwork affiliate bringing memory research to the Inland Empire. Dr Cydney Osano integrates brain health with board-certified obesity medicine experience, serving Riverside patients alongside My-Linh Tong, NP. Located in a retail center near the 91 Freeway.
• Inglewood ClinicalcoreStrategic or Co-development PartnerNetwork affiliate bridging access to cutting-edge memory research for the Inglewood community near SoFi Stadium. Free validated parking on a hospital campus. Addresses a previously underserved population in memory research access.
• West Los Angeles (Ladera Heights)minorStrategic or Co-development PartnerExpansion site of Inglewood Clinical in the richly diverse Ladera Heights area of West LA. Larger space offering the same cutting-edge research access. Conveniently located on La Cienega with free validated garage parking.
• Oakland Clinical (Dr Parenteau)coreStrategic or Co-development PartnerNetwork affiliate offering groundbreaking memory research studies not available elsewhere in the Bay Area, including at UCSF or Stanford. Located in a medical tower in Oakland with Bay and City views and free validated garage parking.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Boston Center for Memory: An independent neurology-focused clinical trial site in the Boston area specializing in Alzheimer's disease trials. Directly comparable as a physician-led, single-therapeutic-area memory research site (one of ICR's coordinators came from Boston Center for Memory).
• ActivMed Practices & Research: An independent, multi-therapeutic clinical research site network operating across the US in CNS, endocrine, and obesity. Directly comparable as another privately-held independent SMO bidding on Phase II–IV trials in the same therapeutic areas as ICR.

Broad incumbents

• Worldwide Clinical Trials: A privately-held global CRO with a recognized CNS/neuroscience franchise, including Alzheimer's. Comparable as a higher-end CRO bidding for Phase II/III AD studies alongside independent sites like ICR.
• Medpace: A mid-to-large global CRO with strong CNS therapeutic expertise. Targets many of the same biotech and mid-pharma sponsors running the neurology and obesity trials ICR also pursues.
• Syneos Health: A global full-service CRO and site network that operates dedicated CNS/Alzheimer's programs. Comparable as a sponsor counterparty for the same Phase II–IV AD trials ICR competes for, though at much larger scale and broader therapeutic portfolio.
• IQVIA: The largest global CRO with deep CNS and Alzheimer's site network relationships. Competes with ICR for sponsor awards on large Phase III AD programs and sets the bar for site turnaround and data quality.
• PAREXEL International: A global CRO with strong CNS/Neurology and Alzheimer's trial experience. Represents the large-cap incumbent competition that sponsor RFPs frequently evaluate against independent sites such as ICR.
• Labcorp Drug Development (Fortrea): A major global CRO with dedicated CNS clinical trial capabilities and site partnerships. Comparable as a broad incumbent competing for the same pharma-sponsored AD and neurology protocols.

Others

• Alto Neuroscience: A clinical-stage CNS biotechnology company running depression and psychiatry trials. Comparable as a sponsor counterparty using the same investigator-site ecosystem ICR participates in, and signals adjacent CNS demand ICR can serve.

Emerging players

• Cognito Therapeutics: A clinical-stage company developing digital and device-based Alzheimer's therapies. Comparable as an emerging AD sponsor that would benefit from ICR's specialized memory research infrastructure and neuroimaging capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/irvineclinical
• LinkedInlinkedin.com/company/irvineclinical

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Irvine Clinical Research